Vaccinex Inc (NASDAQ:VCNX) – Analysts at Oppenheimer issued their Q1 2020 earnings estimates for shares of Vaccinex in a research report issued on Wednesday, November 27th. Oppenheimer analyst L. Gershell anticipates that the company will post earnings per share of ($0.06) for the quarter. Oppenheimer also issued estimates for Vaccinex’s Q2 2020 earnings at ($0.73) EPS, Q3 2020 earnings at ($0.56) EPS, Q4 2020 earnings at ($0.58) EPS and FY2023 earnings at ($3.84) EPS.
Vaccinex (NASDAQ:VCNX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.66) by $0.10. Vaccinex had a negative net margin of 4,740.03% and a negative return on equity of 585.69%. The business had revenue of $0.40 million during the quarter.
Shares of VCNX opened at $4.98 on Monday. The company has a market capitalization of $73.57 million, a PE ratio of -0.96 and a beta of 1.53. Vaccinex has a one year low of $3.32 and a one year high of $8.49. The company’s fifty day moving average price is $5.27 and its 200 day moving average price is $5.55.
Hedge funds and other institutional investors have recently modified their holdings of the business. Creative Planning acquired a new position in shares of Vaccinex during the second quarter worth approximately $55,000. Oppenheimer & Co. Inc. acquired a new stake in shares of Vaccinex in the second quarter worth $87,000. Finally, MSD Partners L.P. acquired a new stake in shares of Vaccinex in the third quarter worth $8,787,000. 10.04% of the stock is currently owned by institutional investors.
Vaccinex, Inc, a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma, and Huntington's disease.
Read More: CD Ladder
Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.